Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 42Rectal Neoplasms 31Colorectal Neoplasms 31Pancreatic Neoplasms 30Neoplasms 26Stomach Neoplasms 20Neoplasm Metastasis 17Colonic Neoplasms 13Unspecified Adult Solid Tumor, Protocol Specific 12Esophageal Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Solid Tumor 7Biliary Tract Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Liver Neoplasms 4Carcinoma, Hepatocellular 4Bile Duct Neoplasms 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Appendiceal Neoplasms 3Anus Neoplasms 3Adenocarcinoma 3Vaginal Neoplasms 2Uterine Cervical Neoplasms 2

Interventions

Radiotherapy 39pembrolizumab 37Carboplatin 37Cisplatin 34Paclitaxel 26Pemetrexed 24Docetaxel 18Nivolumab 17Magnetic Resonance Spectroscopy 17Gemcitabine 17Bevacizumab 17Specimen Handling 16Cyclophosphamide 15osimertinib 14Radiation 13Irinotecan 13Etoposide 13Erlotinib Hydrochloride 12durvalumab 11Topotecan 10Cetuximab 10Radiosurgery 9Immunoglobulin G 8Fluorouracil 8Everolimus 8Disulfides 8Celecoxib 8fludarabine 7Taxes 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lung Neoplasms × Capecitabine × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT00107250 2023-08-04

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

Canadian Cancer Trials Group

Phase 1 Completed
50 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡